In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir (original) (raw)

Abstract

sparkles

AI

The study evaluates the in vitro antihepadnaviral activities of combinations of penciclovir (PCV), lamivudine (3TC), and adefovir (PMEA) against hepatitis B virus (HBV). It highlights the chronic infection rates and associated complications of HBV, discussing the limitations of current therapies and the potential for new nucleoside and nucleoside analogs. The findings indicate synergistic effects of PCV and 3TC in decreasing viral replication, alongside illustrating their safety and efficacy from previous clinical experiences.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (41)

  1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, and L. D. Condreay. 1998. Identification and char- acterization of mutations in hepatitis B virus resistant to lamivudine. Lami- vudine Clinical Investigation Group. Hepatology 27:1670-1677.
  2. Annaert, P., R. Kinget, L. Naesens, E. de Clercq, and P. Augustijns. 1997. Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester pro- drug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm. Res. 14:492-496.
  3. Aye, T. T., A. Bartholomeusz, T. Shaw, S. Bowden, A. Breschkin, J. McMil- lan, P. Angus, and S. Locarnini. 1997. Hepatitis B virus polymerase muta- tions during antiviral therapy in a patient following liver transplantation. J. Hepatol. 26:1148-1153.
  4. Barditch-Crovo, P., J. Toole, C. W. Hendrix, K. C. Cundy, D. Ebeling, H. S. Jaffe, and P. S. Lietman. 1997. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloy- loxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J. Infect. Dis. 176:406-413.
  5. Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
  6. Boni, C., A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, P. Scog- namiglio, R. Boehme, R. Panebianco, F. Fiaccadori, and C. Ferrari. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Investig. 102:968-975.
  7. Civitico, G., Y. Wang, C. Luscombe, N. Bishop, G. Tachedjian, I. Gust, and S. Locarnini. 1990. Antiviral strategies in chronic hepatitis B virus infection. II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J. Med. Virol. 31:90-97.
  8. Civitico, G. M., and S. A. Locarnini. 1994. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 203:81-89.
  9. Cohen Stuart, J. W., C. A. Boucher, D. A. Cooper, G. J. Galasso, D. D. Richman, H. C. Thomas, and R. J. Whitley. 1998. Summary of the Third International Consensus Symposium on Combined Antiviral Therapy. An- tivir. Res. 38:75-93.
  10. Colacino, J. M., and K. A. Staschke. 1998. The identification and develop- ment of antiviral agents for the treatment of chronic hepatitis B virus infec- tion. Prog. Drug Res. 50:259-322.
  11. Colledge, D., S. Locarnini, and T. Shaw. 1997. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 26:216-225.
  12. Danniaoui, E., C. Trepo, and F. Zoulim. 1997. Inhibitory effect of penciclo- vir-triphosphate on duck hepatitis B virus reverse transcription. Antivir. Chem. Chemother. 8:38-46.
  13. Deeks, S. G., A. Collier, J. Lalezari, A. Pavia, D. Rodrigue, W. L. Drew, J. Toole, H. S. Jaffe, A. S. Mulato, P. D. Lamy, W. Li, J. M. Cherrington, N. Hellmann, and J. Kahn. 1997. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 176:1517-1523.
  14. Del Gobbo, V., A. Foli, J. Balzarini, E. De Clercq, E. Balestra, N. Villani, S. Marini, C. F. Perno, and R. Calio. 1991. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleo- tide analogue, on in vivo murine models. Antivir. Res. 16:65-75.
  15. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
  16. Fagan, E. A., E. Lausch, D. Rowell, S. Tekankornpul, H. Rosenblate, D. Ganger, and D. Jensen. 1997. Improvement in protracted complicated hep- atitis B with reduction in residual virus replication using lamivudine/famci- clovir. Hepatology 26(Suppl.):504A. (Abstract 1502.)
  17. Fourel, I., P. Gripon, O. Hantz, L. Cova, V. Lambert, C. Jacquet, K. Wa- tanabe, J. Fox, C. Guillouzo, and C. Trepo. 1989. Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: a useful system for antiviral testing. Hepatology 10:186-191.
  18. Gilson, R. J. C., I. M. Murray-Lyon, M. R. Nelson, S. J. Rice, R. S. Tedder, A. Murray, H. S. Jaffe, N. Hellmann, and I. V. D. Weller. 1998. Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. Hepatology 28(Suppl.):491A. (Abstract 1316.)
  19. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331- 385.
  20. Heathcote, E. J., L. Jeffers, T. Wright, M. Sherman, R. Perillo, S. Sacks, R. Carithers, V. Rustgi, A. Di Bisceglie, V. Balan, A. Murray, J. Rooney, and H. S. Jaffe. 1998. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipovoxil therapy in chronic hep- atitis B: two placebo-controlled phase II studies. Hepatology 28(Suppl.): 317A. (Abstract 1316.)
  21. Heijtink, R. A., G. A. De Wilde, J. Kruining, L. Berk, J. Balzarini, E. De Clercq, A. Holy, and S. W. Schalm. 1993. Inhibitory effect of 9-(2-phospho- nylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antivir. Res. 21:141-153.
  22. Heijtink, R. A., J. Kruining, G. A. de Wilde, J. Balzarini, E. de Clercq, and S. W. Schalm. 1994. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 38:2180-2182.
  23. Hoofnagle, J. H. 1998. Therapy of viral hepatitis. Digestion 59:563-578.
  24. Lai, C. L., R. N. Chien, N. W. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and D. F. Gray. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lami- vudine Study Group. N. Engl. J. Med. 339:61-68.
  25. Lai, C. L., M. F. Yeun, C. C. Cheng, W. M. Wong, T. K. Cheng, and Y. P. Lai. 1998. An open comparative study of lamivudine and famciclovir in the treatment of chronic hepatitis B. Hepatology 27(Suppl.):318A. (Abstract 622.)
  26. Lin, E., C. Luscombe, Y. Y. Wang, T. Shaw, and S. Locarnini. 1996. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 40:413-418.
  27. Main, J., J. L. Brown, C. Howells, R. Galassini, M. Crossey, P. Karayiannis, P. Georgiou, G. Atkinson, and H. C. Thomas. 1996. A double blind, placebo- controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 3:211-215.
  28. Naesens, L., R. Snoeck, G. Andrei, J. Balzarini, and E. De Clercq. 1998. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phos- phonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 8:1-23.
  29. Nicoll, A. J., P. W. Angus, S. T. Chou, C. A. Luscombe, R. A. Smallwood, and S. A. Locarnini. 1997. Demonstration of duck hepatitis B virus in bile duct epithelial cells: implications for pathogenesis and persistent infection. Hepa- tology 25:463-469.
  30. Nicoll, A. J., D. L. Colledge, J. J. Toole, P. W. Angus, R. A. Smallwood, and S. A. Locarnini. 1998. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob. Agents Chemother. 42:3130-3135.
  31. Shaw, T., P. Amor, G. Civitico, M. Boyd, and S. Locarnini. 1994. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 38:719-723.
  32. Shaw, T., and S. Locarnini. 1995. Hepatic purine and pyrimidine metabo- lism: implications for antiviral chemotherapy in viral hepatitis. Liver 15:169- 184.
  33. Shaw, T., and S. Locarnini. 1999. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J. Viral Hepatitis 6:89-106.
  34. Shaw, T., D. Colledge, and S. A. Locarnini. 1997. Synergistic inhibition of in vitro hepadnaviral replication by PMEA and penciclovir or lamivudine. An- tivir. Res. 34:A51. (Abstract 33.)
  35. Shaw, T., S. S. Mok, and S. A. Locarnini. 1996. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 24:996-1002.
  36. Sherker, A., and P. Marion. 1991. Hepadnaviruses and hepatocellular car- cinoma. Annu. Rev. Microbiol. 45:475-508.
  37. Tillman, H. L., C. Trautwein, T. Bock, M. Glowenka, M. Kruger, K. Boker, E. Jakel, R. Pilchmayr, L. Condreay, J. Bruns, M. Desjaurias, J. Gauthier, and M. P. Manns. 1997. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology 26(Suppl.):429A. (Abstract 1202.)
  38. Tuttleman, J. S., J. C. Pugh, and J. W. Summers. 1986. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J. Virol. 58:17-25.
  39. Wu, T. T., L. Coates, C. E. Aldrich, J. Summers, and W. S. Mason. 1990. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175:255-261.
  40. Xiong, X., C. Flores, H. Yang, J. J. Toole, and C. S. Gibbs. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.
  41. Zoulim, F., and C. Trepo. 1998. Drug therapy for chronic hepatitis B: anti- viral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 29:151-168.